HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

IV thrombolysis in very severe and severe ischemic stroke: Results from the SITS-ISTR Registry.

AbstractOBJECTIVE:
To study the safety of off-label IV thrombolysis in patients with very severe stroke (NIH Stroke Scale [NIHSS] scores >25) compared with severe stroke (NIHSS scores 15-25), where treatment is within European regulations.
METHODS:
Data were analyzed from 57,247 patients with acute ischemic stroke receiving IV tissue plasminogen activator in 793 hospitals participating in the Safe Implementation of Thrombolysis in Stroke (SITS) International Stroke Thrombolysis Registry (2002-2013). Eight hundred sixty-eight patients (1.5%) had NIHSS scores >25 and 19,995 (34.9%) had NIHSS scores 15-25. Outcome measures were parenchymal hemorrhage, symptomatic intracerebral hemorrhage, mortality, and functional outcome.
RESULTS:
Parenchymal hemorrhage occurred in 10.7% vs 11.0% (p = 0.79), symptomatic intracerebral hemorrhage per SITS-MOST (SITS-Monitoring Study) in 1.4% vs 2.5% (p = 0.052), death at 3 months in 50.4% vs 26.9% (p < 0.001), and functional independence at 3 months in 14.0% vs 29.0% (p < 0.001) of patients with NIHSS scores >25 and NIHSS scores 15-25, respectively. Multivariate adjustment did not change findings from univariate comparisons. Posterior circulation stroke was more common in patients with NIHSS scores >25 (36.2% vs 7.4%, p < 0.001), who were also more often obtunded or comatose on presentation (58.4% vs 7.1%, p < 0.001). Of patients with NIHSS scores >25, 26.2% were treated >3 hours from symptom onset vs 14.5% with NIHSS scores of 15-25.
CONCLUSIONS:
Our data show no excess risk of cerebral hemorrhage in patients with NIHSS score >25 compared to score 15-25, suggesting that the European contraindication to IV tissue plasminogen activator treatment at NIHSS levels >25 may be unwarranted. Increased mortality and lower rates of functional independence in patients with NIHSS score >25 are explained by higher stroke severity, impaired consciousness on presentation due to posterior circulation ischemia, and longer treatment delays.
AuthorsMichael V Mazya, Kennedy R Lees, David Collas, Viiu-Marika Rand, Robert Mikulik, Danilo Toni, Nils Wahlgren, Niaz Ahmed
JournalNeurology (Neurology) Vol. 85 Issue 24 Pg. 2098-106 (Dec 15 2015) ISSN: 1526-632X [Electronic] United States
PMID26546630 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2015 American Academy of Neurology.
Chemical References
  • Tissue Plasminogen Activator
Topics
  • Aged
  • Aged, 80 and over
  • Brain Ischemia (diagnosis, drug therapy)
  • Female
  • Humans
  • Infusions, Intravenous
  • Internationality
  • Male
  • Middle Aged
  • Registries
  • Severity of Illness Index
  • Stroke (diagnosis, drug therapy)
  • Thrombolytic Therapy (methods)
  • Tissue Plasminogen Activator (administration & dosage)
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: